David Berry (inventor)

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

Retrieved on: 
Friday, September 13, 2024
Seres, Conference, David Berry (inventor), Therapy

CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that the Company, will participate in the Cantor Global Healthcare Conference and Eric Shaff, President and Chief Executive Officer, will represent Seres in a presentation on September 18, 2024 at 3:05 p.m.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that the Company, will participate in the Cantor Global Healthcare Conference and Eric Shaff, President and Chief Executive Officer, will represent Seres in a presentation on September 18, 2024 at 3:05 p.m.
  • ET.
  • A video webcast of the presentation will be available under the “Events and Presentations” tab on the “Investors and News” section of Seres’ website.
  • The replay will become available approximately one hour after the event and will be archived for 21 days.

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Retrieved on: 
Thursday, September 12, 2024
Acute myeloid leukemia, Fungal infection, Intensive care medicine, ITT, Haematopoietic system, Cohort, Bloodstream infections, Blood, Patient, Therapy, Safety, Prevalence, FDA, Arm, Disease, Chronic liver disease, ID, Conference, Cancer, Cis, HSCT, David Berry (inventor), Food, Febrile neutropenia, Breakthrough therapy, Death, Gastrointestinal tract, Interval (mathematics), Literature, CMC, Acute leukemia, Mortality, Myelodysplastic syndrome, Risk, Odds ratio, Incidence, Infection, GI, Conference call, Bacteria, Graft-versus-host disease

ET today

Key Points: 
  • ET today
    CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today reports topline clinical data from Cohort 2 of its SER-155 Phase 1b placebo-controlled study in patients undergoing allo-HSCT.
  • SER-155 is an investigational live oral biotherapeutic cultivated from clonal master cell banks designed to prevent GI-derived bacterial bloodstream infections and other pathogen-associated complications.
  • The Company also intends to evaluate SER-155 in additional patient populations that have a high risk of serious bacterial infections.
  • “Given our encouraging clinical results and the severe consequences of bacterial infections, we will pursue Breakthrough Therapy designation with the FDA.

2024 Microbiome Market Trends Report Featuring Seres Therapeutics, Rebiotix, IFF (DuPont), Chr. Hansen (Novonesis), Nestle, Probi, Lactobio, Pivot Bio, and LanzaTech - ResearchAndMarkets.com

Retrieved on: 
Friday, August 30, 2024
Vitamins, Supplements, Pharmaceutical, Fitness & Nutrition, Health, David Berry (inventor), FDA, Fishery, Agriculture, Livestock, Fermentation, Bacteria, Probiotic, U.S. FDA, Therapy, Marketing, Medication, Carbon, Skin care, Ethanol, Antibiotics

In the microbiome therapeutics market, some microbiome drugs have succeeded in commercialization.

Key Points: 
  • In the microbiome therapeutics market, some microbiome drugs have succeeded in commercialization.
  • The microbiome market is growing not only in therapeutics but also in food-related markets.
  • In the U.S., Seres Therapeutics' SER-109 and Rebiotix's RBX-2660 received U.S. FDA approval and entered the market successfully in 2023.
  • This report will cover the efforts of companies involved in the microbiome market.

MCRB Investigation Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seres Therapeutics, Inc. Assets Is Fair to Shareholders

Retrieved on: 
Friday, August 9, 2024
Class Action Lawsuit, Professional Services, Legal, Therapy, David Berry (inventor), Advertising, Sale, Fraud

Halper Sadeh LLC, an investor rights law firm, is investigating whether Seres Therapeutics, Inc.’s (NASDAQ: MCRB) sale of its VOWST microbiome therapeutic business to Société des Produits Nestlé S.A is fair to Seres shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether Seres Therapeutics, Inc.’s (NASDAQ: MCRB) sale of its VOWST microbiome therapeutic business to Société des Produits Nestlé S.A is fair to Seres shareholders.
  • After the sale was announced, Seres’s stock price fell $0.27 per share or 21% to close at $1.01 per share on August 6, 2024.
  • On behalf of Seres shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors

Retrieved on: 
Monday, June 24, 2024
Merck & Co., Acquisition, Business development, Schering-Plough, OMEGA, Business administration, Messenger, Corporation, Merck, M&A, David Berry (inventor), Fairleigh Dickinson University, Senior, Knowledge, Flagship Pioneering, Retirement, Therapy, Villanova University, Omega, Management

CAMBRIDGE, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the election of Richard N. Kender to its Board of Directors following its annual meeting of stockholders.

Key Points: 
  • CAMBRIDGE, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the election of Richard N. Kender to its Board of Directors following its annual meeting of stockholders.
  • “Richard has had a long and impressive career in the industry and brings deep expertise across multiple facets of the pharmaceutical business, as well as experience serving as a director for several public biotech companies,” said Chris Schade, Chairman of the Omega Therapeutics Board of Directors and Growth Partner at Flagship Pioneering.
  • Most recently, he served as Senior Vice President, Business Development and Corporate Licensing from 2000 until his retirement in 2013.
  • Mr. Kender currently serves on the board of directors of Seres Therapeutics, POXEL SA, Longeveron Inc. and Bicycle Therapeutics.

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, June 7, 2024
Calendar, David Berry (inventor), Therapy, Employment, Compensation, Pharmaceutical industry

These stock options and inducement RSUs are subject to the terms of the Seres Therapeutics, Inc. 2022 Employment Inducement Award Plan (the “Inducement Plan”).

Key Points: 
  • These stock options and inducement RSUs are subject to the terms of the Seres Therapeutics, Inc. 2022 Employment Inducement Award Plan (the “Inducement Plan”).
  • The Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to their entering into employment with Seres pursuant to Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Plan was adopted by Seres’ board of directors in December 2022.
  • The stock options have an exercise price of $1.14 per share.

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, May 8, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Oaktree Capital Management, Sale, FDA, Variometer, Gastroenterology, David Berry (inventor), Acceleration, Safety, Clostridioides, Risk, Commercial, Research, Chronic liver disease, Recurrence, Cohort, Fast track (FDA), ATM, Clostridioides difficile infection, Allo, GI, Therapy, Data, Patient, Infection, CDI, HSCT, ID, G&A, Pharmaceutical industry

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2024 financial results and provided business updates.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2024 financial results and provided business updates.
  • These clinical results could further validate the vast potential of microbiome therapeutics in preventing adverse outcomes linked to gastrointestinal pathogens,” continued Mr. Shaff.
  • In the first quarter of 2024, approximately 1,411 completed prescription enrollment forms were received for VOWST and there were approximately 1,083 new patient starts.
  • Seres’ share of the VOWST net loss for the first quarter of 2024 was $7.1 million, which was included in the Company’s operating results within Collaboration (profit) loss sharing—related party.

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

Retrieved on: 
Monday, May 6, 2024
Biotechnology, Pharmaceutical, Health, Therapy, ID, David Berry (inventor)

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 8, 2024 at 8:30 a.m.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 8, 2024 at 8:30 a.m.
  • ET to discuss first quarter 2024 financial results and provide business updates.
  • To join the live webcast, please visit the “Investors and News” section of the Seres website at www.serestherapeutics.com .
  • A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, May 6, 2024
Biotechnology, Pharmaceutical, Health, Employment, David Berry (inventor), Therapy, Compensation, Calendar, Pharmaceutical industry

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on May 1, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 9,367 shares of its common stock to two new employees, consisting of stock options to purchase 6,244 shares of common stock and restricted stock units (“RSUs”) covering 3,123 shares of its common stock.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on May 1, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 9,367 shares of its common stock to two new employees, consisting of stock options to purchase 6,244 shares of common stock and restricted stock units (“RSUs”) covering 3,123 shares of its common stock.
  • These stock options and inducement RSUs are subject to the terms of the Seres Therapeutics, Inc. 2022 Employment Inducement Award Plan (the “Inducement Plan”).
  • The Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to their entering into employment with Seres pursuant to Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Plan was adopted by Seres’ board of directors in December 2022.

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Disease, Allo, Infection, Incidence, Patient, Immune tolerance, Gastrointestinal tract, GI, David Berry (inventor), Mortality, Bacteria, HSCT, Bloodstream infections, Graft-versus-host disease, Therapy, Chronic liver disease, Safety, Immunodeficiency, Data, Pharmaceutical industry

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in patients who received Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT).

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in patients who received Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT).
  • Infections are a leading cause of mortality and morbidity in this immunocompromised patient population.
  • Our pending clinical results could validate the promise of microbiome therapeutics to prevent poor outcomes associated with pathogens in the GI tract.
  • Study Cohort 2, which includes 45 participants, incorporates a randomized, double-blinded placebo-controlled 1:1 design to further evaluate safety and engraftment, as well as clinical outcomes.